[1]
Younce JR, Davis AA, Black KJ. A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson's Disease. Journal of Parkinson's disease. 2019:9(1):63-71. doi: 10.3233/JPD-181448. Epub
[PubMed PMID: 30475775]
Level 2 (mid-level) evidence
[2]
Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, Servis M, Walaszek A, Buckley P, Lenzenweger MF, Young AS, Degenhardt A, Hong SH, (Systematic Review). The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. The American journal of psychiatry. 2020 Sep 1:177(9):868-872. doi: 10.1176/appi.ajp.2020.177901. Epub
[PubMed PMID: 32867516]
Level 1 (high-level) evidence
[3]
Su L, Lu Z, Shi S, Xu Y. Ziprasidone, haloperidol and clonazepam intramuscular administration in the treatment of agitation symptoms in Chinese patients with schizophrenia: A network meta-analysis. General psychiatry. 2018:31(2):e000016. doi: 10.1136/gpsych-2018-000016. Epub 2018 Nov 10
[PubMed PMID: 30582129]
Level 1 (high-level) evidence
[4]
Sabe M, Zhao N, Crippa A, Kaiser S. Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials. NPJ schizophrenia. 2021 Sep 13:7(1):43. doi: 10.1038/s41537-021-00171-2. Epub 2021 Sep 13
[PubMed PMID: 34518532]
Level 1 (high-level) evidence
[5]
Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS drug reviews. 2007 Summer:13(2):137-77
[PubMed PMID: 17627670]
[6]
Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU. Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam medical journal. 2016 Sep:52(3):159-72. doi: 10.4068/cmj.2016.52.3.159. Epub 2016 Sep 23
[PubMed PMID: 27689026]
[7]
Shim IH, Bahk WM, Woo YS, Yoon BH. Pharmacological Treatment of Major Depressive Episodes with Mixed Features: A Systematic Review. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. 2018 Nov 30:16(4):376-382. doi: 10.9758/cpn.2018.16.4.376. Epub
[PubMed PMID: 30466209]
Level 1 (high-level) evidence
[8]
Macaluso M, Preskorn SH. Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing. Journal of psychiatric practice. 2018 Nov:24(6):416-419. doi: 10.1097/PRA.0000000000000345. Epub
[PubMed PMID: 30395549]
[9]
De Berardis D, Serroni N, Marini S, Rapini G, Valchera A, Fornaro M, Mazza M, Iasevoli F, Martinotti G, Di Giannantonio M. Successful ziprasidone monotherapy in a case of delusional parasitosis: a one-year followup. Case reports in psychiatry. 2013:2013():913248. doi: 10.1155/2013/913248. Epub 2013 May 16
[PubMed PMID: 23762722]
Level 3 (low-level) evidence
[10]
Patkar A, Gilmer W, Pae CU, Vöhringer PA, Ziffra M, Pirok E, Mulligan M, Filkowski MM, Whitham EA, Holtzman NS, Thommi SB, Logvinenko T, Loebel A, Masand P, Ghaemi SN. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PloS one. 2012:7(4):e34757. doi: 10.1371/journal.pone.0034757. Epub 2012 Apr 24
[PubMed PMID: 22545088]
Level 1 (high-level) evidence
[11]
Markowitz JD, Narasimhan M. Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options. Psychiatry (Edgmont (Pa. : Township)). 2008 Oct:5(10):29-36
[PubMed PMID: 19724721]
Level 1 (high-level) evidence
[12]
Rivière J, van der Mast RC, Vandenberghe J, Van Den Eede F. Efficacy and Tolerability of Atypical Antipsychotics in the Treatment of Delirium: A Systematic Review of the Literature. Psychosomatics. 2019 Jan-Feb:60(1):18-26. doi: 10.1016/j.psym.2018.05.011. Epub 2018 May 31
[PubMed PMID: 30181002]
Level 1 (high-level) evidence
[13]
Wilson MP,Pepper D,Currier GW,Holloman GH Jr,Feifel D, The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. The western journal of emergency medicine. 2012 Feb;
[PubMed PMID: 22461918]
Level 3 (low-level) evidence
[14]
Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. The American journal of psychiatry. 1991 Nov:148(11):1474-86
[PubMed PMID: 1681750]
[15]
Rao NP, Remington G. Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials. Expert opinion on pharmacotherapy. 2014 Feb:15(3):373-83. doi: 10.1517/14656566.2014.873790. Epub 2013 Dec 20
[PubMed PMID: 24354659]
Level 3 (low-level) evidence
[16]
Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I, Altamura AC. Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Clinical pharmacokinetics. 2018 Dec:57(12):1493-1528. doi: 10.1007/s40262-018-0664-3. Epub
[PubMed PMID: 29915922]
[17]
Gandelman K, Alderman JA, Glue P, Lombardo I, LaBadie RR, Versavel M, Preskorn SH. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. The Journal of clinical psychiatry. 2009 Jan:70(1):58-62
[PubMed PMID: 19026256]
Level 1 (high-level) evidence
[18]
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Azorin JM, Yatham L, Mosolov S, Möller HJ, Kasper S, Members of the WFSBP Task Force on Bipolar Affective Disorders Working on this topic. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2018 Feb:19(1):2-58. doi: 10.1080/15622975.2017.1384850. Epub 2017 Nov 3
[PubMed PMID: 29098925]
[19]
Larsen ER, Damkier P, Pedersen LH, Fenger-Gron J, Mikkelsen RL, Nielsen RE, Linde VJ, Knudsen HE, Skaarup L, Videbech P, Danish Psychiatric Society, Danish Society of Obstetrics and Gynecology, Danish Paediatric Society, Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. Acta psychiatrica Scandinavica. Supplementum. 2015:(445):1-28. doi: 10.1111/acps.12479. Epub
[PubMed PMID: 26344706]
[20]
Hoover RK, Alcorn H Jr, Lawrence L, Paulson SK, Quintas M, Luke DR, Cammarata SK. Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment. Journal of clinical pharmacology. 2018 Jun:58(6):814-822. doi: 10.1002/jcph.1077. Epub 2018 Mar 26
[PubMed PMID: 29578585]
[21]
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2019 Apr:67(4):674-694. doi: 10.1111/jgs.15767. Epub 2019 Jan 29
[PubMed PMID: 30693946]
[22]
Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. The Annals of pharmacotherapy. 2002 May:36(5):839-51
[PubMed PMID: 11978164]
[23]
Ali SN, Bazzano LA. Hyponatremia in Association With Second-Generation Antipsychotics: A Systematic Review of Case Reports. Ochsner journal. 2018 Fall:18(3):230-235. doi: 10.31486/toj.17.0059. Epub
[PubMed PMID: 30275787]
Level 3 (low-level) evidence
[24]
Bark N, Lawson N, Trigoboff E, Varadi R, Grace J, Olympia J, Sindhu N, Watson T, El-Defrawi M, Roy P. Among the Severely Mentally Ill, Who Responds to Ziprasidone? Clinical schizophrenia & related psychoses. 2018 Summer:12(2):77-85. doi: 10.3371/CSRP.BALA123015. Epub
[PubMed PMID: 30040474]
[25]
Sedhai YR, Atreya A, Phuyal P, Basnyat S, Pokhrel S. Case Report: Ziprasidone induced neuroleptic malignant syndrome. F1000Research. 2021:10():124. doi: 10.12688/f1000research.51094.1. Epub 2021 Feb 17
[PubMed PMID: 33763203]
Level 3 (low-level) evidence
[26]
Bell JD, Hall C, Sandall J. Ziprasidone Associated Neuroleptic Malignant Syndrome. Kansas journal of medicine. 2021:14():82-83. doi: 10.17161/kjm.vol1411970. Epub 2021 Mar 19
[PubMed PMID: 33763185]
[27]
Honigberg MC, Bui MP, Coconcea C. A case of ziprasidone associated with acutely worsened diabetes mellitus. Psychosomatics. 2013 May-Jun:54(3):304-5. doi: 10.1016/j.psym.2012.08.011. Epub
[PubMed PMID: 23680062]
Level 3 (low-level) evidence
[28]
Scheen AJ, De Hert M. [Drug-induced diabetes mellitus: the exemple of atypical antipsychotics]. Revue medicale de Liege. 2005 May-Jun:60(5-6):455-60
[PubMed PMID: 16035311]
[29]
Pierce CE, Bouri K, Pamer C, Proestel S, Rodriguez HW, Van Le H, Freifeld CC, Brownstein JS, Walderhaug M, Edwards IR, Dasgupta N. Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts. Drug safety. 2017 Apr:40(4):317-331. doi: 10.1007/s40264-016-0491-0. Epub
[PubMed PMID: 28044249]
[30]
Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Therapeutics and clinical risk management. 2017:13():757-777. doi: 10.2147/TCRM.S117321. Epub 2017 Jun 29
[PubMed PMID: 28721057]
[31]
Wilson A, Filatov A, Azhar M, Swerdloff M, Husain Wilson S. Ziprasidone-Induced Oculogyric Crisis in a 74-Year-Old Female. Cureus. 2020 Jul 9:12(7):e9100. doi: 10.7759/cureus.9100. Epub 2020 Jul 9
[PubMed PMID: 32789046]
[32]
Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. British journal of clinical pharmacology. 2000:49 Suppl 1(Suppl 1):65S-70S
[PubMed PMID: 10771457]
[33]
Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC. 2016 May:149(3):139-52. doi: 10.1177/1715163516641136. Epub 2016 Apr 8
[PubMed PMID: 27212965]
[34]
Khasawneh FT, Shankar GS. Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia. Cardiology research and practice. 2014:2014():273060. doi: 10.1155/2014/273060. Epub 2014 Feb 4
[PubMed PMID: 24649390]
[35]
Aronow WS, Shamliyan TA. Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders. Annals of translational medicine. 2018 Apr:6(8):147. doi: 10.21037/atm.2018.03.17. Epub
[PubMed PMID: 29862236]
[36]
Jeon SW, Kim YK. Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome. International journal of molecular sciences. 2017 Oct 18:18(10):. doi: 10.3390/ijms18102174. Epub 2017 Oct 18
[PubMed PMID: 29057817]
[37]
Crotti L, Celano G, Dagradi F, Schwartz PJ. Congenital long QT syndrome. Orphanet journal of rare diseases. 2008 Jul 7:3():18. doi: 10.1186/1750-1172-3-18. Epub 2008 Jul 7
[PubMed PMID: 18606002]
[38]
Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World psychiatry : official journal of the World Psychiatric Association (WPA). 2018 Oct:17(3):341-356. doi: 10.1002/wps.20567. Epub
[PubMed PMID: 30192094]
[39]
Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. The American journal of psychiatry. 2012 Sep:169(9):900-6. doi: 10.1176/appi.ajp.2012.12030342. Epub
[PubMed PMID: 22952071]
[40]
Shah AA, Aftab A, Coverdale J. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? Journal of psychiatric practice. 2014 May:20(3):196-206. doi: 10.1097/01.pra.0000450319.21859.6d. Epub
[PubMed PMID: 24847993]
[41]
Urban AE, Cubała WJ. Therapeutic drug monitoring of atypical antipsychotics. Psychiatria polska. 2017 Dec 30:51(6):1059-1077. doi: 10.12740/PP/65307. Epub 2017 Dec 30
[PubMed PMID: 29432503]
[42]
Girard TD, Exline MC, Carson SS, Hough CL, Rock P, Gong MN, Douglas IS, Malhotra A, Owens RL, Feinstein DJ, Khan B, Pisani MA, Hyzy RC, Schmidt GA, Schweickert WD, Hite RD, Bowton DL, Masica AL, Thompson JL, Chandrasekhar R, Pun BT, Strength C, Boehm LM, Jackson JC, Pandharipande PP, Brummel NE, Hughes CG, Patel MB, Stollings JL, Bernard GR, Dittus RS, Ely EW, MIND-USA Investigators. Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. The New England journal of medicine. 2018 Dec 27:379(26):2506-2516. doi: 10.1056/NEJMoa1808217. Epub 2018 Oct 22
[PubMed PMID: 30346242]
[43]
Nelson JC, Spyker DA. Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000-2014. The American journal of psychiatry. 2017 May 1:174(5):438-450. doi: 10.1176/appi.ajp.2016.16050523. Epub 2017 Jan 31
[PubMed PMID: 28135844]
Level 3 (low-level) evidence
[44]
Martino D, Karnik V, Osland S, Barnes TRE, Pringsheim TM. Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2018 Jan 1:63(11):706743718777392. doi: 10.1177/0706743718777392. Epub 2018 Jan 1
[PubMed PMID: 29758999]
Level 3 (low-level) evidence